Banco Santander S.A. boosted its position in shares of Eli Lilly and Company (NYSE:LLY – Get Rating) by 21.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,972 shares of the company’s stock after purchasing an additional 2,514 shares during the quarter. Banco Santander S.A.’s holdings in Eli Lilly and were worth $4,002,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently modified their holdings of the company. AllSquare Wealth Management LLC acquired a new position in shares of Eli Lilly and in the 4th quarter valued at approximately $28,000. HWG Holdings LP acquired a new position in Eli Lilly and during the 4th quarter worth approximately $28,000. Icapital Wealth LLC acquired a new position in Eli Lilly and during the 1st quarter worth approximately $28,000. Leverty Financial Group LLC acquired a new position in Eli Lilly and during the 4th quarter worth approximately $29,000. Finally, FSB Premier Wealth Management Inc. acquired a new position in Eli Lilly and during the 4th quarter worth approximately $30,000. 82.75% of the stock is currently owned by institutional investors and hedge funds.
Eli Lilly and Price Performance
Eli Lilly and stock opened at $301.32 on Friday. The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 1.60. The company has a market capitalization of $286.30 billion, a PE ratio of 48.06, a P/E/G ratio of 2.26 and a beta of 0.35. Eli Lilly and Company has a 12 month low of $220.20 and a 12 month high of $335.33. The stock has a 50-day moving average price of $316.10 and a two-hundred day moving average price of $289.01.
Eli Lilly and Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 9th. Stockholders of record on Monday, August 15th will be given a dividend of $0.98 per share. The ex-dividend date of this dividend is Friday, August 12th. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.30%. Eli Lilly and’s dividend payout ratio (DPR) is 62.52%.
Insider Transactions at Eli Lilly and
In other news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, June 1st. The stock was sold at an average price of $313.44, for a total transaction of $313,440.00. Following the completion of the transaction, the chief accounting officer now directly owns 6,274 shares in the company, valued at $1,966,522.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 700 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, May 18th. The stock was sold at an average price of $302.00, for a total value of $211,400.00. Following the completion of the sale, the insider now directly owns 105,472,666 shares in the company, valued at $31,852,745,132. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 1st. The shares were sold at an average price of $313.44, for a total value of $313,440.00. Following the completion of the sale, the chief accounting officer now directly owns 6,274 shares of the company’s stock, valued at approximately $1,966,522.56. The disclosure for this sale can be found here. Insiders sold 1,195,396 shares of company stock worth $380,134,601 over the last ninety days. 0.12% of the stock is owned by insiders.
Analyst Ratings Changes
A number of brokerages have recently issued reports on LLY. UBS Group upped their price objective on Eli Lilly and to $335.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 27th. Wells Fargo & Company increased their price target on Eli Lilly and from $280.00 to $305.00 in a research note on Friday, April 29th. The Goldman Sachs Group increased their price objective on Eli Lilly and from $234.00 to $264.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. SVB Leerink started coverage on Eli Lilly and in a research report on Monday, May 23rd. They set an “outperform” rating and a $341.00 price objective on the stock. Finally, StockNews.com cut Eli Lilly and from a “strong-buy” rating to a “buy” rating in a research report on Friday. Three research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and currently has an average rating of “Moderate Buy” and a consensus price target of $316.06.
About Eli Lilly and
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
- Get a free copy of the StockNews.com research report on Eli Lilly and (LLY)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.